Search Results

Pharm Country

Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington’s Disease Patients

PTC Therapeutics, Inc. shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington’s disease patients.

June 20, 2024

·

7 min read

Drug Development

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Wave Life Sciences Ltd. today announced positive results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD).

June 25, 2024

·

11 min read

Biotech Bay

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

10x Genomics, Inc., a leader in single cell and spatial biology, announced the commercial availability of its Visium HD Spatial Gene Expression product.

March 26, 2024

·

5 min read

Press Releases

Fresenius Medical Care Grows Number of U.S. Patients Using Company’s Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software

September 4, 2024

·

4 min read

Pharm Country

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA ® HD (aflibercept) Injection 8 mg.

April 29, 2024

·

17 min read

Press Releases

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

November 7, 2024

·

15 min read

Drug Development

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

January 23, 2024

·

2 min read

Pharm Country

Soterix Medical Launches MxN-GO EEG System for Wire-free HD-tES and EEG

Soterix Medical Inc., the global leader in non-invasive brain stimulation and synergistic monitoring technologies, announced the launch of MxN-GO EEG, a combined High Definition transcranial Electrical Stimulation and EEG system with a unique untethered design.

April 30, 2024

·

2 min read

Drug Development

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Takeda and Pfizer announced that the German Hodgkin Study Group will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology Annual Meeting and at the 29th European Hematology Association Annual Meeting.

June 1, 2024

·

32 min read

Pharm Country

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg.

March 8, 2024

·

14 min read